| 0.593 -0.032 (-5.17%) | 01-26 12:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.88 | 1-year : | 1.04 |
| Resists | First : | 0.75 | Second : | 0.89 |
| Pivot price | 0.62  |
|||
| Supports | First : | 0.54 | Second : | 0.44 |
| MAs | MA(5) : | 0.63 |
MA(20) : | 0.62 |
| MA(100) : | 0.65  |
MA(250) : | 0.91 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.6 |
D(3) : | 53.8 |
| RSI | RSI(14): 41.3 |
|||
| 52-week | High : | 1.79 | Low : | 0.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FEMY ] has closed above bottom band by 29.7%. Bollinger Bands are 59.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.65 - 0.65 | 0.65 - 0.66 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.62 - 0.63 | 0.63 - 0.63 |
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Fri, 16 Jan 2026
Femasys Receives Nasdaq Extension to Regain Listing Compliance - The Globe and Mail
Wed, 14 Jan 2026
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - GlobeNewswire
Wed, 14 Jan 2026
Nasdaq gives Femasys more time to fix sub-$1 share price by July 2026 - Stock Titan
Tue, 25 Nov 2025
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - Stocktwits
Fri, 14 Nov 2025
Femasys Announces Third Quarter Financial Results for 2025 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 60 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 8.3 (%) |
| Held by Institutions | 8.1 (%) |
| Shares Short | 1,950 (K) |
| Shares Short P.Month | 1,960 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | -501 % |
| Return on Assets (ttm) | -69.4 % |
| Return on Equity (ttm) | -376.3 % |
| Qtrly Rev. Growth | 31.3 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.87 |
| PEG Ratio | 0 |
| Price to Book value | 5.95 |
| Price to Sales | 17.18 |
| Price to Cash Flow | -1.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|